Derazantinib is a multi-kinase inhibitor under investigation as an active pharmaceutical ingredient. It is being studied in clinical trials for conditions involving FGFR2 gene fusions.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1234356-69-4
Tenapanor hydrochloride
pharmaceutical raw material
Rivastigmine
pharmaceutical raw material
Tenapanor
pharmaceutical raw material
Prulifloxacin
pharmaceutical raw material
(6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine
KPJDVVCDVBFRMU-AREMUKBSSA-N
COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F